Gero

Thanks @Nasdaq for celebrating our recent partnership with @chugai_cc to develop novel therapies for age-related diseases. 🧬🧬 Read the news: shorturl.at/JZAck

The hackathon kicks off on October 7 (9 AM SF / 6 PM CET) with @DeryaTR_’s inspiring opening speech and the presentation of challenges. Join the army of good — now over 700 participants strong. ✨ Late registration is still open @ hackaging.ai!

Our Chief Business Officer @Alexey_Kadet will be speaking at @LSXLeaders in Boston next week on Sept 17. 🧬🧬 More info: shorturl.at/uV1TF

In this episode (# 357) of The Drive, Brian Kennedy, Ph.D., shares insights from ongoing human aging studies, including clinical trials of rapamycin and how dosing strategies, timing, and exercise may influence outcomes. bit.ly/40sLs10

We’re thrilled to welcome @BKennedy_aging to our Board of Directors! Read our release: globenewswire.com/news-release/2…

New Power Pair in #longevity science — Gero(@hacking_aging) x Chugai Pharmaceutical (@chugai_cc). Chugai harness its proprietary antibody engineering technologies with Gero's AI platform to develop anti-aging therapies— Deal value may top $1 billion. biospace.com/business/roche…

The partnership will give Chugai access to Gero’s artificial intelligence technology to discover novel targets in aging-related diseases. Chugai will then develop antibody-based drugs based on the findings. #AI #biospace hubs.li/Q03w3sCD0

.@endpts spoke with our CEO @fedichev about the recent Chugai deal and what this means for #longevity @ky_lahucik endpoints.news/roche-backed-c…

Thanks @LongevityTech for covering our deal with Chugai. Milestones plus escalating royalties position Gero for industry-leading longevity returns in major therapeutic alliance with Chugai. 🔥🔥 Read the article: 👇👇 longevity.technology/news/ai-driven…

Thanks @biospace for covering our deal with Chugai today to develop novel therapies for age-related chronic diseases. 🧬🧬 Read the article: biospace.com/business/roche…

Roche's Chugai places $250M wager on Gero's AI to crack age-related disease $RHHBY firstwordpharma.com/story/5979054

BREAKING: Gero Signs Potential Multi-Billion-$  Deal to Fuel Our Mission to Stop Aging  -- A few years ago, my son, aged five at the time, asked what happened to the dinosaurs. After learning their sad story, he told me he wanted to fly to the Moon and defend Earth from falling comets. He began assembling his crew—quickly running out of family members and turning to his grandparents—but then stopped and asked: “Dad... Grandpa and Grandma are already old. It will be hard for them to shoot down comets. Can we make it so people don’t age?” At that tender age, he couldn’t yet fully grasp death, but he already understood aging—and its cruel way of stealing our strength and time. This story has played out billions of times in human history: a child realizes, for the first time, that life is finite. But maybe—just maybe—his generation will be the first to hear a different answer. Today, we took a step toward that answer. Together with Chugai Pharmaceutical (a member of Roche group), we announced a partnership to develop therapies that target the root causes of major age-related diseases. At Gero, we’ve spent the last 15 years building physics-informed AI models, trained on massive longitudinal datasets tracking human biology over years. These models revealed something critical: in long-lived mammals like humans, aging is mostly an entropic process—slow, irreversible damage that accumulates over time. But diseases? They are failures of individual systems—failures that occur faster in aging bodies but, crucially, are still actionable. Some of these failure points are shared across multiple diseases, and targeting these shared vulnerabilities could lead to therapies that fight multiple diseases at once. When we started our journey, there were no examples of success to follow. What we had was the belief that science works—and that complex phenomena like aging and chronic diseases could be understood through first principles borrowed from other sciences like physics, and with the help of emerging AI and machine learning tools. We also had no clear idea how to fund such an enterprise. Our inspiration came from nature itself—from mammals like naked mole rats and bats, which show little to no signs of aging over long lifespans. Things are moving fast. The recent success of GLP-1 drugs (Ozempic, Wegovy) has already shown what’s possible: a single drug class improving metabolic health, heart disease, obesity, and more. What once seemed like science fiction is now reality. And yet, as I argued in my Lifespan's column, these are still just our first flying machines. The real challenge is to build the rockets—to address the fundamental physics of aging, not just its symptoms. Our models predict three levels of intervention against aging in humans  (as always, please do not forget to like, follow and repost before scrolling down for more explanations and links): 1/2

We’re excited to announce a potential multi-billion licensing agreement with Chugai to develop novel therapies for age-related diseases. #longevity 🧬🧬 shorturl.at/HC6I8

Gero unveils AI model for small molecule design without structure #longevity #longevityinnovation #AI longevity.technology/news/gero-unve…

𝐀𝐈 𝐍𝐞𝐰𝐬: Singapore based @hacking_aging, a ompany focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery. CEO @fedichev explains the idea. Full video: biotechtv.com/post/gero-june…

Thanks @fwpharma for featuring the launch of ProtoBind-Diff small molecule AI discovery model. 🧬🧬 Read the article: firstwordpharma.com/story/5976106

🚀 We’re excited to announce the launch of ProtoBind-Diff, a masked diffusion language model that generates small molecules conditioned solely on protein sequences. #AI #drugdiscovery 🧬🧬 Read our release: alturl.com/twjet

Excited to share that I will be joining @athena_dao_’s Demo Day on Wednesday, June 25th, at 9:00 AM PT / 12:00 PM ET / 6:00 PM CET. I’ll be talking about my work APPLY TO ATTEND 👇 lu.ma/0aki5i4g

Could scientists have been getting it wrong all along? In Ep. 6 of Decoding Longevity, @fedichev ( @hacking_aging ) explains why animal models are misleading us—and what to do about it.

Yes, aging won’t be solved by simple fixes.
Meet polypharmacology by design — AI-crafted compounds from Gero & Scripps extended worm lifespan by up to +74%. Aging is complex. Now our tools are too. Thanks Eleanor Garth @tinkinggumbel for the brilliant write-up. Link 👇